Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluticasone Propionate/Albuterol Sulfate Combination in Asthma
NCT06664619Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Dec 2024
- Primary completion
- Oct 2026
- Modality
- Orthosteric Ligands
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of fluticasone propionate nasal spray and salbutamol in asthma (4 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Forced Expiratory Volume in one second Area Under the Effect Curve at 4 weeks and Trough Forced Expiratory Volume in one second at 4 weeks. Started Dec 2024; status: completed.
02
Drugs
fluticasone propionate nasal spraysalbutamol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06664619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06664619.